Anis A H, Lynd L D, Wang X H, King G, Spinelli J J, Fitzgerald M, Bai T, Paré P
Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, BC.
CMAJ. 2001 Mar 6;164(5):625-31.
There is considerable controversy about the regular use of short-acting beta-agonists for the treatment of asthma. Although case-control studies have suggested that excessive use of these drugs may worsen asthma control and increase the risk of fatal or near-fatal asthma, the controversy remains unresolved because of the confounding that exists among disease control, disease severity and the use of short-acting beta-agonists. Whatever the cause-and-effect relation between the use of short-acting beta-agonists and disease severity, we hypothesized that their excessive use, in conjunction with underuse of inhaled corticosteroids, would be a marker for poorly controlled asthma and excessive use of health care resources.
To characterize the pattern of health services utilization among asthmatic patients taking various doses of inhaled beta-agonists and corticosteroids in British Columbia, we linked the relevant health administrative databases. All patients between 5 and 50 years of age for whom a prescription for a short-acting beta-agonist was filled in 1995 and whose prescription data were captured through the provincial drug plan were included in a retrospective analysis of prescriptions for asthma drugs, physician prescribing patterns and health services utilization. Patients' use of asthma medication was classified as appropriate (low doses of short-acting beta-agonist and high doses of inhaled corticosteroid) or inappropriate (high doses of short-acting beta-agonist and low doses of inhaled corticosteroid), and the 2 resulting groups were compared, by means of logistic, Poisson and gamma regression, for differences in prescribing patterns, physician visits and use of hospital resources.
A total of 23,986 patients were identified as having filled a prescription for a short-acting beta-agonist (for inhalation) in 1995. Of these, 3069 (12.8%) filled prescriptions for 9 or more canisters of beta-agonist, and of this group of high-dose beta-agonist users, 763 (24.9%) used no more than 100 micrograms/day of inhaled beclomethasone. On average, those with inappropriate use of beta-agonists visited significantly more physicians for their prescriptions (1.8 v. 1.4), and each of these physicians on average wrote significantly more prescriptions for asthma medications per patient than the physicians who prescribed to appropriate users (5.2 v. 2.5 prescriptions). Patients with inappropriate use were more likely to be admitted to hospital (adjusted relative risk [RR] 1.68, 95% confidence interval [CI] 1.25-2.26), were admitted to hospital more frequently (adjusted RR 1.81, 95% CI 1.41-2.32) and were more likely to require emergency admission (adjusted RR 1.93, 95% CI 1.35-2.77).
Despite the widespread distribution of guidelines for asthma pharmacotherapy, inappropriate use of asthma medications persists (specifically excessive use of inhaled short-acting beta-agonists combined with underuse of inhaled corticosteroids). Not only are patients who use medication inappropriately at higher risk for fatal or near-fatal asthma attacks, but, as shown in this study, they use significantly more health care resources than patients with appropriate medication use.
对于常规使用短效β受体激动剂治疗哮喘存在相当大的争议。尽管病例对照研究表明过度使用这些药物可能会使哮喘控制恶化并增加致命或近乎致命哮喘的风险,但由于疾病控制、疾病严重程度和短效β受体激动剂使用之间存在混杂因素,这一争议仍未得到解决。无论短效β受体激动剂的使用与疾病严重程度之间的因果关系如何,我们推测过度使用短效β受体激动剂并同时吸入糖皮质激素使用不足,将是哮喘控制不佳和医疗资源过度使用的一个标志。
为了描述不列颠哥伦比亚省服用不同剂量吸入性β受体激动剂和糖皮质激素的哮喘患者的卫生服务利用模式,我们将相关的卫生行政数据库进行了关联。1995年开具短效β受体激动剂处方且处方数据通过省级药物计划获取的所有5至50岁患者,被纳入哮喘药物处方、医生处方模式和卫生服务利用的回顾性分析。患者的哮喘药物使用被分类为适当(低剂量短效β受体激动剂和高剂量吸入性糖皮质激素)或不适当(高剂量短效β受体激动剂和低剂量吸入性糖皮质激素),并通过逻辑回归、泊松回归和伽马回归比较这两组在处方模式、医生就诊次数和医院资源使用方面的差异。
共有23986名患者在1995年被确定开具了短效β受体激动剂(吸入用)处方。其中,3069名(12.8%)患者开具了9罐或更多罐β受体激动剂的处方,在这组高剂量β受体激动剂使用者中,763名(24.9%)患者每天吸入倍氯米松不超过100微克。平均而言,β受体激动剂使用不当的患者因处方看医生的次数明显更多(1.8次对1.4次),而且这些医生平均为每位患者开具的哮喘药物处方比为适当使用者开处方的医生显著更多(5.2张对2.5张处方)。使用不当的患者更有可能住院(调整后相对风险[RR]为1.68,95%置信区间[CI]为1.25 - 2.26),住院频率更高(调整后RR为1.81,95%CI为1.41 - 2.32),并且更有可能需要急诊入院(调整后RR为1.93,95%CI为1.35 - 2.77)。
尽管哮喘药物治疗指南已广泛传播,但哮喘药物使用不当的情况仍然存在(具体为吸入短效β受体激动剂过度使用且吸入糖皮质激素使用不足)。不仅药物使用不当的患者发生致命或近乎致命哮喘发作的风险更高,而且如本研究所示,他们使用的医疗资源比药物使用适当的患者显著更多。